The FDA has approved these medications for use in patients with type 2 diabetes and for weight loss in individuals meeting certain criteria, such as BMI and weight-related conditions
Glucagon, the surprising third dial, nudges the body to spend more energy and helps clear fat from the liver
The cagrilintide-retatrutide combination stays within the incretin and satiety hormone family, while tesamorelin-retatrutide combines two entirely different hormonal systems
The team found that semaglutide users experienced between a 40% and 70% reduction in alzheimers risk compared to those receiving insulin or other diabetes treatments
The authors conclude: In this real-world study where half of patients discontinued GLP-1-based treatment within a year after initiation, not losing weight was associated with worse clinical outcomes while larger reductions were associated with decreased risks
For complete information, please visit the Mary Ann Liebert, Inc